Suppr超能文献

使用氟伐他汀降低胆固醇期间,血浆纤维蛋白原增加,但血小板内环状核苷酸、血浆内皮素-1、因子VII和新蝶呤水平未变。

Increasing plasma fibrinogen, but unchanged levels of intraplatelet cyclic nucleotides, plasma endothelin-1, factor VII, and neopterin during cholesterol lowering with fluvastatin.

作者信息

Gottsäter A, Anwaar I, Lind P, Mattiasson I, Lindgärde F

机构信息

Department of Vascular and Renal Diseases, University of Lund, University Hospital MAS, Malmö, Sweden.

出版信息

Blood Coagul Fibrinolysis. 1999 Apr;10(3):133-40. doi: 10.1097/00001721-199904000-00004.

Abstract

Lipid-lowering statin treatment reduces cardiovascular morbidity and mortality and improves endothelial function in patients with hypercholesterolemia. The aim of the present study was to evaluate plasma levels of fibrinogen, factor VII, and the macrophage-derived inflammatory mediator neopterin during lipid lowering. In addition, the endothelial production of platelet antiaggregatory and vasodilatory factors such as nitric oxide and prostacyclin, and vasoconstrictive factors such as endothelin-1, was assessed. Plasma fibrinogen, factor VII, endothelin-1, and the neopterin and intraplatelet nitric oxide and prostacyclin mediators cyclic 3'-5'guanosine monophosphate (cGMP) and cyclic 3'-5'adenosine monophosphate (cAMP) were measured before and 6 months after the institution of treatment with fluvastatin in 17 patients (eight men and nine women, median age 60 years) with vascular disease and previously untreated hypercholesterolemia. After 6 months, a decrease of 1.62 mmol/l [1.26-2.18 (19%); P < 0.01] was noted in levels of total cholesterol, and a decrease of 1.70 mmol/l [1.52-2.30 (28%); P < 0.01] in levels of low-density lipoprotein cholesterol. Plasma levels of fibrinogen had increased [from 4.81 g/l (4.26-5.27) to 5.17 g/l (4.81-5.67); P < 0.05], whereas no significant changes had occurred in intraplatelet levels of cGMP [decrease by 0.05 pmol/10(9) platelets (-0.17 to 0.24); NS], cAMP [decrease by 0.13 pmol/10(9) platelets (-0.37 to 0.86); NS], plasma endothelin-1 [decrease by 0.05 pg/ml (-0.60 to 0.70); NS], plasma factor VII [from 1.14 IE/ml (0.58-1.38) to 1.22 IE/ml (0.96-1.46); NS], or plasma neopterin [from 8.6 nmol/l (7.1-11.5) to 8.7 nmol/l (7.9-11.3); NS]. In conclusion, during cholesterol-lowering treatment with fluvastatin, plasma levels of fibrinogen increased whereas intraplatelet cyclic nucleotide levels and plasma endothelin-1, factor VII and neopterin levels were unchanged.

摘要

降脂他汀类药物治疗可降低高胆固醇血症患者的心血管发病率和死亡率,并改善其内皮功能。本研究的目的是评估降脂过程中血浆纤维蛋白原、凝血因子VII以及巨噬细胞衍生的炎症介质新蝶呤的水平。此外,还评估了内皮细胞产生的血小板抗聚集和血管舒张因子(如一氧化氮和前列环素)以及血管收缩因子(如内皮素-1)。对17例(8例男性和9例女性,中位年龄60岁)患有血管疾病且此前未接受治疗的高胆固醇血症患者,在使用氟伐他汀治疗前及治疗6个月后,测定了血浆纤维蛋白原、凝血因子VII、内皮素-1、新蝶呤以及血小板内一氧化氮和前列环素介质环磷酸鸟苷(cGMP)和环磷酸腺苷(cAMP)的水平。6个月后,总胆固醇水平下降了1.62 mmol/l [1.26 - 2.18(19%);P < 0.01],低密度脂蛋白胆固醇水平下降了1.70 mmol/l [1.52 - 2.30(28%);P < 0.01]。血浆纤维蛋白原水平升高[从4.81 g/l(4.26 - 5.27)升至5.17 g/l(4.81 - 5.67);P < 0.05],而血小板内cGMP水平[下降0.05 pmol/10⁹血小板(-0.17至0.24);无显著性差异]、cAMP水平[下降0.13 pmol/10⁹血小板(-0.37至0.86);无显著性差异]、血浆内皮素-1水平[下降0.05 pg/ml(-0.60至0.70);无显著性差异]、血浆凝血因子VII水平[从1.14 IE/ml(0.58 - 1.38)升至1.22 IE/ml(0.96 - 1.46);无显著性差异]或血浆新蝶呤水平[从8.6 nmol/l(7.1 - 11.5)升至8.7 nmol/l(7.9 - 11.3);无显著性差异]均未发生显著变化。总之,在使用氟伐他汀降低胆固醇治疗期间,血浆纤维蛋白原水平升高,而血小板内环核苷酸水平以及血浆内皮素-1、凝血因子VII和新蝶呤水平未发生变化。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验